高齡35歲以上病患於誘導排卵中施打LH可提高胚胎著床率與懷孕率
The use of recombinant luteinizing hormone in patients undergoing assisted
reproductive techniques with advanced reproductive age: a systematic review and
meta-analysis.
Source
Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver
National Institute of Child Health and Human Development, National Institutes of
Health, Bethesda, Maryland.
Abstract
OBJECTIVE:
To evaluate the effect of recombinant LH in assisted reproduction technology
(ART) cycles in patients of advanced reproductive age.
DESIGN:
A systematic review and meta-analysis.
SETTING:
Published randomized controlled clinical trials comparing recombinant LH plus
recombinant FSH versus recombinant FSH only in patients of advanced reproductive
age.
PATIENT(S):
Patients 35 years and older undergoing assisted reproduction.
INTERVENTION(S):
Recombinant LH plus recombinant FSH controlled ovarian hyperstimulation (COH)
versus recombinant FSH stimulation only in assisted reproduction cycles.
MAIN OUTCOME MEASURE(S):
Implantation and clinical pregnancy.
RESULT(S):
Seven trials were identified that met inclusion criteria and comprised 902
assisted reproduction technology cycles. No differences in serum E(2) on the day
of hCG administration were reported in any trials. Two trials reported lower
oocyte yield and one trial reported lower metaphase II oocyte yield in the
recombinant LH-supplemented group. One trial reported higher fertilization rates
in the recombinant LH-supplemented group. In a fixed effect model, implantation
was higher in the recombinant LH-supplemented group (odds ratio 1.36, 95%
confidence interval 1.05-1.78). Similarly, clinical pregnancy was increased in
the recombinant LH-supplemented group (odds ratio 1.37, 95% confidence interval
1.03-1.83).
CONCLUSION(S):
The addition of recombinant LH to ART cycles may improve implantation and
clinical pregnancy in patients of advanced reproductive age.
沒有留言:
張貼留言